Comparison of different HCV viral load and genotyping assays

Journal of Clinical Virology

Volumn 28, Issue 1, 2003, Pages 27-37

  Anderson, Jonathan C ^a   Simonetti, Josephine ^b   Fisher, Dennis G ^c   Williams, James ^b   Yamamura, Yasuhiro ^d   Rodriguez, Nayra ^d   Sullivan, Daniel G ^e   Gretch, David R ^e   McMahon, Brian ^b   Williams, Kandace J ^f  

^a UNIVERSITY OF ALASKA ANCHORAGE   (United States)

^b ALASKA NATIVE MEDICAL CENTER   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d PONCE SCHOOL OF MEDICINE   (Puerto Rico)

^e UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^f MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

Genotype; Hepatitis C virus; Interlaboratory comparison; Serum viral load

Indexed keywords

DNA FRAGMENT;

ANTIBIOTIC THERAPY; ARTICLE; BIOASSAY; BIOLOGICAL MONITORING; BLOOD LEVEL; CALIBRATION; CONTROLLED STUDY; DNA SEQUENCE; GENE AMPLIFICATION; GENOTYPE; HEALTH CARE ORGANIZATION; HEPATITIS C VIRUS; HUMAN; INTERMETHOD COMPARISON; LABORATORY; NUCLEOTIDE SEQUENCE; PATIENT; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RELIABILITY; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; STANDARD; STATISTICAL ANALYSIS; VIRUS DETECTION; VIRUS LOAD;

EVALUATION STUDIES; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; NUCLEIC ACID AMPLIFICATION TECHNIQUES; POLYMERASE CHAIN REACTION; REAGENT KITS, DIAGNOSTIC; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; VIRAL LOAD;

EID: 0042090454     PISSN: 13866532     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6532(02)00235-4     Document Type: Article

References (34)

1. Alter M.J., Kruszon-Moran D., Nainan O.V., McQuillan G.M., Gao F., Moyer L.A., et al. The epidemiology of hepatitis C virus infection in the United States, 1988 through 1994. N. Engl. J. Med. 341:1999;556-562.
2. Arens M. Clinically relevant sequence-based genotyping of HBV, HCV, CMV and HIV. J. Clin. Virol. 22:2001;11-29.
3. Bukh J., Miller R.H., Purcell R.H. Genetic heterogeneity of hepatitis C virus; quasispecies and genotypes. Semin. Liver Dis. 15:1995;41-63.
4. Carithers R.L., Marquarot A., Gretch D.R. Diagnostic testing for hepatitis C. Semin. Liver Dis. 20:2000;159-171.
5. Cary NC. SAS/STAT User's Guide, Version 8. SAS Institute, Inc.; 1999.
6. Chen Y., Cooper D.L., Ehrlich G.D. Comparative analysis of three nucleic acid-based detection systems for hepatitis C virus RNA in plasma from liver transplant recipients. Mol. Cell. Probes. 10:1996;331-336.
7. Cohen J. A coefficient of agreement for nominal scales. Educ. Psychol. Measurement. 20:1960;37-46.
8. Cohen J. The scientific challenge of hepatitis C. Science. 285:1999;26-30.
9. Davidson F., Simmonds P., Ferguson J.C., Jarvis L.M., Dow B.C., Follett E.A., et al. Survey of major genotypes and subtypes of hepatitis C virus using RFLP of sequences amplified from the 5′ non-coding region. J. Gen. Virol. 76:1995;1197-1204.
10. Di Bisceglie A.M., Order S.E., Klein J.L., Waggoner J.G., Sjogren M.H., Kuo G., et al. The role of chronic viral hepatitis in hepatocellular carcinoma in the United States. Am. J. Gastroenterol. 86:1991;335-338.
11. EASL International Consensus Conference on Hepatitis C. Concensus Statement. J. Hepatol. 1999;30:956-61.
12. Fisher D.G., Hoffman P. The adjusted Rand statistic: a SAS macro. Psychometrika. 53:1988;417-423.
13. Hawkins A., Davidson F., Simmonds P. Comparison of plasma virus loads among individuals infected with hepatitis C virus (HCV) genotypes 1, 2, and 3 by quantiplex HCV RNA assay version 1 and 2, Roche Monitor Assay, and an in-house limiting dilution method. J. Clin. Microbiol. 35:1997;187-192.
14. Hepatitis C Fact Sheet, CDC Website.
15. Hubert L., Arabie P. Camparing partitions. J. Classification. 2:1985;193-218.
16. Jorgenson P.A., Neuwald P.D. Standardized hepatitis C virus RNA panels for nucleic acid testing assays. J. Clin. Virol. 20:2001;35-40.
17. Kawai S., Yokosuka O., Kanda T., Imazeki F., Maru Y., Saisho H. Quantification of hepatitis C virus by Taqman PCR: comparison with HCV Amplicor Monitor assay. J. Med. Virol. 58:1999;121-126.
18. Le Pogam S., Dubois F., Christen R., Raby C., Cavicchini A., Goudeau A. Comparison of DNA enzyme immunoassay and line probe assays (Inno-LiPA HCV I and II) for hepatitis C virus genotyping. J. Clin. Microbiol. 36:1998;1461-1463.
19. Management of Hepatitis C, NIH Consensus Statement Online.
20. Martell M., Gomez J., Esteban J.I., Sauleda S., Quer J., Cabot B., et al. High-throughput Real-Time reverse transcription-PCR quantitation of hepatitis C virus RNA. J. Clin. Microbiol. 37:1999;327-332.
21. McHutchinson J.G., Gordon S.C., Schiff E.R., Shiffman M.L., Lee W.M., Rustgi U.K., et al. Interferon alpha-2b alone or in combination with Ribavirin as initial treatment for chronic hepatitis C. N. Engl. J. Med. 339:1998;1485-1492.
22. Mellor J., Hawkins A., Simmonds P. Genotype dependence of Hepatitis C virus load measurements in commercially available quantitative assays. J. Clin. Microbiol. 1999;37.
23. Morey L., Agresti A. The measurement of classification agreement: an adjustment to the Rand statistic for chance agreement. Educ. Psychol. Measurement. 44:1984;33-37.
24. Morishima C., Gretch D.R. Clinical use of hepatitis C virus tests for diagnosis and monitoring during therapy. Keefe E.B. Treatment of chronic hepatitis C. 1999;717-740 Saunders, WB, Philadelphia.
25. Pawlotsky J.-M., Bouvier-Alias M., Hesode C., Darthuy F., Remire J., Dhumeaux D. Standardization of hepatitis C virus quantification. Hepatology. 32:2000;654-659.
26. Poynard T., Marcellin P., Lee S.S., Niederau C., Minuk G.S., Ideo G., et al. Randomized trial of Interferon alpha-2b plus Ribavirin for 48 weeks or 24 weeks versus Interferon alpha-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
27. Rand W.M. Objective criteria for the evaluation of clustering methods. J. Am. Stat. Assoc. 66:1971;846-850.
28. Saldanha J. Standardization: a progress report. Biologicals. 27:1999;285-289.
29. Saldanha J., Lelie N., Heath A. Establishment of the First International Standard for Nucleic Acid Amplification Technology (NAT) Assays for HCV RNA. Vox Sang. 76:1999;149-158.
30. Simmonds P. Variability of hepatitis C virus. Hepatology. 21:1995;570-583.
31. Takeuchi T., Katsume A., Tanaka T., Abe A., Inoue K., Tsukiyama-Kohara K., et al. Real-Time detection system for quantification of hepatitis C virus genome. Gastroenterology. 116:1999;636-642.
32. Thomas D.L., Lemon S.M. Hepatitis C. Mandell G.L., Bennett J.F., Dolin R. Principles and practice of disease. 2000;1736-1760.
33. Tibor L., Funk E., Beller M. Hepatitis C. State Alaska Epidemiol. Bull. 1999;3.
34. Zein N.N. Clinical significance of hepatitis C virus genotypes. Clin. Microbiol. Rev. 13:2000;223-235.